|
Palo Alto, CA, September 3, 2004 – Telik, Inc. (Nasdaq:
TELK) announced that company management will present an update at
the Thomas Weisel Healthcare Tailwinds 2004 Conference on Wednesday,
September 8, 2004 at 8:00 a.m. Eastern time (5:00 a.m. Pacific time)
at the Four Seasons Hotel in Boston. A live webcast of the presentation
will be accessible at Telik’s website, www.telik.com.
An archive of the webcast will be available on the Telik website
through September 13, 2004.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company working
to discover, develop and commercialize small molecule drugs to treat
serious diseases. The company’s most advanced drug development
candidate is TELCYTA™ (TLK286), a tumor-activated small molecule
product candidate that is in Phase 3 registration trials in advanced
ovarian and non-small cell lung cancer. Telik’s product candidates
were discovered using its proprietary drug discovery technology,
TRAP, which enables the rapid and efficient discovery of small molecule
drug candidates. Additional information is available at www.telik.com
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2004
Press Releases2003
Press ReleasesEvents
|
